Therapeutic approaches in arterial thrombosis (Q28187576)

Journal of Thrombosis and Haemostasis

Europe PubMed Central

title

Therapeutic approaches in arterial thrombosis (English)

0 references

0 references

D R Phillips

1

0 references

P B Conley

series ordinal

2

0 references

U Sinha

series ordinal

3

0 references

P Andre

series ordinal

4

0 references

language of work or name

English

0 references

publication date

August 2005

0 references

published in

0 references

volume

3

0 references

issue

8

0 references

page(s)

1577-89

0 references

cites work

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Scientific and therapeutic advances in antiplatelet therapy

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

G13 is an essential mediator of platelet activation in hemostasis and thrombosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Profile and prevalence of aspirin resistance in patients with cardiovascular disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Common variations in platelet glycoproteins: pharmacogenomic implications

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Identification of the platelet ADP receptor targeted by antithrombotic drugs

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Coordinate interactions of Csk, Src, and Syk kinases with [alpha]IIb[beta]3 initiate integrin signaling to the cytoskeleton

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 April 2017

1 reference

https://api.crossref.org/works/10.1111/J.1538-7836.2005.01418.X

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

21 April 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Variability in platelet responsiveness to clopidogrel among 544 individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Synthesis and biological activity of 2-alkylated deoxyadenosine bisphosphate derivatives as P2Y(1) receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

The platelet CD40L/GP IIb-IIIa axis in atherothrombotic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Platelet receptor interplay regulates collagen-induced thrombus formation in flowing human blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Phosphoinositide 3-kinases and the regulation of platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Defective platelet activation in G alpha(q)-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Signaling through Gi family members in platelets. Redundancy and specificity in the regulation of adenylyl cyclase and other effectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Hematopoietic reconstitution of SLP-76 corrects hemostasis and platelet signaling through alpha IIb beta 3 and collagen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Requirement for CD154 in the progression of atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Recollections of the development of flow devices for studying mechanisms of hemostasis and thrombosis in flowing whole blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X

Soluble CD40 Ligand in Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1538-7836.2005.01418.X